InvestorsHub Logo
Followers 39
Posts 1575
Boards Moderated 0
Alias Born 02/26/2013

Re: None

Friday, 07/12/2013 9:10:45 AM

Friday, July 12, 2013 9:10:45 AM

Post# of 91007
IntelliCell BioSciences Announces Frederick Frank as Executive Advisor to Board of Directors

Dr. Steven Victor, CEO of IntelliCell, stated "We are very pleased to have Mr. Frank join our organization and gain access to his biotechnology expertise and leadership. He has made a tremendous impact on our industry and specifically for the companies he has chosen to be affiliated with. We look forward to his counsel as we strive to achieve new landmarks in regenerative medicine."
Added Mr. Frank "Like many heralded advances in the life sciences field, the early promise and potential creates pronounced enthusiasm. Often the realization of that promise takes longer and is more complex than forecasted. And, inevitably, disappointment sets in. The promise of utilizing therapeutic stem cells is just such an example. But now it's here. Under the leadership of Dr. Steven Victor at IntelliCell BioSciences, the promise of tomorrow is a reality today."

Mr. Frank joined Peter J. Solomon in 2009 from Barclays Capital where he was Vice Chairman. He began his investment banking career at Smith, Barney & Co. Inc. in 1958, where he attained the positions of Co-Head of Research, Vice President and Director. Subsequently he joined Lehman Brothers, Inc., in 1969, as a partner. At Lehman, Mr. Frank provided investment banking services to an extensive number of companies in the pharmaceutical, biotechnology, healthcare services, medical device and nutraceutical industries, and was involved in hundreds of financings, strategic alliances and merger and acquisition transactions in the global healthcare industry. Mr. Frank is a director of Landec Corporation, a publicly-traded material science company, and formerly a director of Pharmaceutical Product Development, Inc., a publicly-traded contract research organization. Mr. Frank previously served as Chairman of the Board of Epix Pharmaceuticals, Inc., a publicly-traded pharmaceutical company. He is Chairman of the National Genetics Foundation, a past director of the Salk Institute, a member of the Pharmaceutical Executive Magazine advisory board and the Journal of Life Sciences, the former Chairman of the Board of The Irvington Institute for Immunological Research, a former member of the Advisory Board of The Harvard School of Public Health, a past member of the advisory board of the Johns Hopkins Bloomberg School of Public Health and he serves on the Advisory Board of the Massachusetts Institute of Technology Center for Biomedical Innovation. He serves on the Yale School of Management Advisory Board. Mr. Frank holds a B.A. from Yale University and an M.B.A. from the Stanford Graduate School of Business.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.